Interleukin-1 inhibition in Behçet’s disease

Donato Rigante, Antonio Vitale, Giuseppe Lopalco, Carlo Selmi, Mauro Galeazzi, Florenzo Iannone, Luca Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

27 Citazioni (Scopus)

Abstract

Behçet's disease (BD) is a systemic inflammatory disorder characterized by a protean clinical spectrum and an enigmatic pathogenesis. After being classified as an autoimmune disorder, spondyloarthritis and vasculitis, today BD is considered at the crossroad between autoimmune and auto-inflammatory syndromes. Many pathogenetic, clinical and therapeutic clues support this recent interpretation, enabling novel treatment choices such as interleukin (IL)-1 inhibition. Thus, in the last decade the IL-1 receptor antagonist anakinra and the anti-IL-1β monoclonal antibody canakinumab were increasingly administered in BD patients resistant to standard therapies, leading to interesting results and intriguing new pathogenetic implications. However, further studies are essential to both establish how the innate and acquired immune systems interact in BD patients and identify the best way of administering anti-IL-1 agents with regard to dosage, interval of administration, and organ response.
Lingua originaleEnglish
pagine (da-a)171-176
Numero di pagine6
RivistaIsrael Medical Association Journal
Volume2016
Stato di pubblicazionePubblicato - 2016

Keywords

  • Behçet's disease

Fingerprint Entra nei temi di ricerca di 'Interleukin-1 inhibition in Behçet’s disease'. Insieme formano una fingerprint unica.

Cita questo